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Abstract: Classical congenital adrenal hyperplasia (CAH) caused by pathogenic variants in the
steroid 21-hydroxylase gene (CYP21A2) is a severe life-threatening condition. We present a detailed
investigation of the molecular and functional characteristics of a novel pathogenic variant in this gene.
The patient, 46 XX newborn, was diagnosed with classical salt wasting CAH in the neonatal period
after initially presenting with ambiguous genitalia. Multiplex ligation-dependent probe analysis
demonstrated a full deletion of the paternal CYP21A2 gene, and Sanger sequencing revealed a novel de
novo CYP21A2 variant c.694–696del (E232del) in the other allele. This variant resulted in the deletion
of a non-conserved single amino acid, and its functional relevance was initially undetermined.
We used both in silico and in vitro methods to determine the mechanistic significance of this
mutation. Computational analysis relied on the solved structure of the protein (Protein-data-bank ID
4Y8W), structure prediction of the mutated protein, evolutionary analysis, and manual inspection.
We predicted impaired stability and functionality of the protein due to a rotatory disposition of
amino acids in positions downstream of the deletion. In vitro biochemical evaluation of enzymatic
activity supported these predictions, demonstrating reduced protein levels to 22% compared to the
wild-type form and decreased hydroxylase activity to 1–4%. This case demonstrates the potential
of combining in-silico analysis based on evolutionary information and structure prediction with
biochemical studies. This approach can be used to investigate other genetic variants to understand
their potential effects.
Keywords: congenital adrenal hyperplasia; CYP21A2; in silico; protein structure; VUS; consurf




































































Int. J. Mol. Sci. 2020, 21, 5857 2 of 11
1. Introduction
Congenital adrenal hyperplasia (CAH), one of the most frequent inborn errors of metabolism,
comprises a group of autosomal recessive disorders of adrenal steroidogenesis (OMIM 201910).
Abnormalities in the steroid 21-hydroxylase account for the majority of cases [1]. Impaired function
of this enzyme results in varying degrees of cortisol and aldosterone deficiencies and consequently
increased production of the adrenocorticotropic hormone (ACTH). This leads to chronic
over-stimulation of the adrenal gland and increased synthesis of androgens starting in the first weeks
of gestation. Steroid 21-hydroxylase deficiency has a broad spectrum of clinical presentations ranging
from severe, classical CAH that presents early after birth to the mild late-onset form (also referred
to as non-classical CAH) [2]. Neonatal screening programs report the incidence of classical CAH as
being approximately 1:15,000 live births [3]. The incidence of the non-classical form is much higher
at about 1:200–1:1000 worldwide. There are clear genotype–phenotype correlations reflecting the
21-hydroxylase residual enzymatic activity. Mutations leading to complete inactivation of steroid
21-hydroxylase are usually associated with a classical CAH phenotype, whereas those with significant
residual enzymatic activity usually present with a non-classical CAH phenotype [2]. The steroid
21-hydroxylase enzyme is a member of the cytochrome P450 group of oxidases [4]. These enzymes
contain a single heme group that absorbs light with a wavelength maximum at 450 nm in their reduced
monoxide-bound states. The steroid 21-hydroxylase consists of 495 amino acids and is localized in the
membrane of the endoplasmic reticulum facing the cytosol where it catalyzes the 21-hydroxylation of
two natural substrates, progesterone and 17-hydroxyprogesterone [2,4–6]. The protein structure of
human steroid 21-hydroxylase was solved (Protein Databank ID 4y8w), using X-ray crystallography,
in the presence of the heme and progesterone or 17-hydroxyprogesterone [7,8]. This protein has
13 alpha helices and 9 beta strands, all organized around the heme.
The steroid 21-hydroxylase gene CYP21A2 is located on the short arm of chromosome 6 (6p21.3)
within the human leukocyte antigen complex and it includes 10 exons. It is adjacent to the pseudogene
CYP21A1P, with which it shares 98% sequence identity [1,5]. The CYP21A2 gene has been characterized
and studied in detail, and multiple genetic lesions have been published [9]. Most of the described
disease-causing variants are likely to be the consequence of non-homologous recombination or gene
conversion events between the gene and the pseudogene [5,10–12].
We describe a novel CYP21A2 variant causing in-frame deletion of a single amino acid found
in a compound heterozygote state with a larger deletion comprising the whole CYP21A2 gene.
The patient had severe classical salt-wasting CAH. We present an extensive study of this new
mutation and its effect on both the structure and function of the enzyme. Based on the in-silico
analysis of the three-dimensional molecular model for CYP21A2 and the in vitro biochemical




The patient was born at 36 weeks’ gestation after premature spontaneous rupture of membranes,
and her birth weight was 2415 g (0.12 weight z-score). The pregnancy was spontaneous, and the
results of routine gestational ultrasound examinations were normal. Amniocentesis was performed
due to advanced maternal age (38 years) and it revealed a 46 XX karyotype. The parents are
of Ashkenazi-Jewish origin, with no consanguinity, and no known history of CAH in the family.
Physical examination at birth revealed signs compatible with classical salt wasting CAH, including
clitoromegaly, fused labial folds with a single urogenital opening at the base of the phallus, and no
palpable gonads, in accordance with stage 3 on the Prader scale [13]. Laboratory tests on the 2nd day of
life and during an episode of significant respiratory distress demonstrated an elevated testosterone level
of 30 nmol/L (normal values 0.7–2.2 nmol/L) a 17OHP level of 27 nmol/L (normal range 2–70 nmol/L)
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and a relatively low cortisol level of 152 nmol/L. Abdominal ultrasound demonstrated bilaterally
enlarged adrenal glands. She was clinically suspected of having CAH and hydrocortisone treatment
was initiated. Hyponatremia and hyperkalemia with urinary salt wasting were noted at 10 days of age,
and treatment with fludrocortisone and salt supplementation was added. Cystoscopy at 1 month of
age demonstrated a 2-cm urogenital tunnel. Two surgical procedures were performed: she underwent
meatoplasty at 12 months of age and a feminizing genitoplasty at 2.5 years of age. Throughout infancy
and childhood, standard doses of hydrocortisone and fludrocortisone were required for control of her
disease, although the 17OHP levels were increased up to >60 nmol/L (normal range 2–6 nmol/L) on
several occasions during her follow-up. Salt supplementation was gradually tapered after the 2nd year
of life. The patient is growing well and her neurological development is normal.
2.2. DNA Studies
MLPA analysis demonstrated a heterozygote deletion that included the CYP21A2 gene, and this
CYP21A2 deletion was detected in the paternal sample as well. Sequencing of the CYP21A2
(NM_000500.7) gene revealed an additional CYP21A2 in-frame deletion of 3 nucleotides encoding
glutamic acid, c.694_696del; E232del (p.Glu232del). This variant was absent in both parents’ sequencing
analysis, and therefore assumed to be de novo. It also had not been previously described and its
functional relevance was undetermined.
2.3. In Silico Analysis of Protein Structure and Function
ConSurf [14–18] analysis of CYP21A2 and its homologues demonstrated evolutionarily conserved
residues of structural and functional importance. We used the ConSurf server for the pdb structure
4y8wA, employing default parameters (150 homologues). Figure 1A shows the relevant part of
the structure that was colored by evolutionary conservation. The evolutionary conservation scale
in ConSurf ranges from 1 (non-conserved, colored in cyan) to 9 (highly conserved, colored in burgundy).
Generally speaking, helix G (following the helix-naming scheme of Pallan et al. [7]), which hosts E232,
is peripheral and mostly variable. Of relevance here, all of the residues in this helix that face the solvent,
and E232 in particular, are variable (namely, the residues Q228, E232, K233, H236, E239, and M240).
Indeed, a mutation of M240K was observed, and it was reported to be non-harmful [19]. E232, which is
colored in cyan to indicate that it is not evolutionarily conserved, is remote from the substrate, and its
side chain faces outward towards the solvent. We predicted the deletion of E232 to have an impact
on the residues within the same helix (helix G). There are 3.6 residues per alpha-helix turn, therefore,
the impact of the deletion is to shorten the helix by approximately 1/3 of a turn, and to alter the position
of each of the downstream residues by turning it back or rotating it (by approximately 1/3 of a turn).
This structural change is expected to impair protein stability. Helix G on the surface of the protein
faces the buried helix I. The side chains of the residues R234, D235, and V238 in helix G face the side
chains of the residue H283 in the helix I, and their shapes are complementary with the H positioned
in a groove formed by the R, D, and V. This positions helix G properly in place. The electrostatics also
contribute to securing the position of helix G, with the positive charge of the H283 fitting into the
negatively charged groove. Indeed, these four residues are very well conserved (R234, D235, and V238
have the maximal consurf score of 9, and H283 has that consurf score of 8). Thus, we suggest that the
deletion of the residue E232 is harmful to the stability of the protein because of its impact on the R234,
D235, and V238 located 2, 3, and 6 residues ahead in the polypeptide chain. The deletion of the residue
at the beginning of helix G, and the rotation outwards of these residues (R234, D235) likely disrupts
the packing of the two helices against each other, disrupting the protein’s overall fold.
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Figure 1. Highlighting evolutionary and structural information relevant to our case in the CYP21A2
structure. Legend: (A): t releva t part of the CYP21A2 structure c lored by evolutiona y conservation.
The evolutionary conservation scale in ConSurf ranges from 1 (non-conserved, colored in cyan) to
9 (highly conserved, colored in burgundy). (B): The native CYP21A2 structure (4y8w), in which the
hydrogen at the tail of the R234 side hain hydrogen-bonds with t e progest rone’s O3, helping position
the progesterone so that its carbon atom C21 on the other end lies near the heme. (C): Highlighting
several structural elements: helices G and I are shown in magenta and blue, and residues E232,
R234, D235, V238, and H283 are highlighted in different colors, with their sidechains shown as sticks.
(D): Zooming in on the region where helix G and helix I touch each other, and showing the side chains of
the relevant residues (as sticks—left panel, and spheres—right panel), the H283 (in purple) is seen to be
positioned in the groove formed by the R, D, and V. The distances between the ring of H283 and the side
chains of these residues are 4.1A (V238), 4.8A (D235), and 5.9A (R234). (E): The electrostatic potential
of helix G (ranging from red for negatively charged to blue for positively charged) shows the groove
that holds H283. (F): The side chains of the three PDB homologues (3qz1, a bovine homologue and
6b82 a zebra fish homologue) of the P45021A2 are shown superimposed. (G): The predicted structure
by Phyre2 [20]. For clarity of representation, we show only helix G in magenta, R234 in red, and the
bound substrates from the WT structure; the predicted R234 is facing away from the progesterone.
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This structural change has further significance due to its impact on residue R234, which participates
in positioning the CYP21A2 ligand, and thus has a particularly important role in the function of the
protein. In the native structure (4y8w), the hydrogen at the tail of the R234 side chain hydrogen bonds
with the progesterone’s O3, helping to position the progesterone so that its carbon atom C21 on the
other end lies near the heme iron (Figure 1B). The rotameric state of residue R234 is very similar among
the homologues of known structures. Figure 1C shows the three PDB homologues: 4y8w (human,
pink), 3qz1 (bovine, gray), and 6b82 (zebra fish, gray). In the insert, the three side chains are seen to be
superimposed, such that the hydrogen is in the same spatial position, i.e., facing inward, where it can
interact with the progesterone. Finally, in support of the functional importance of R234, previous studies
have documented mutations with impaired function in this residue. Barbaro et al. [21] described two
patients with an R234G mutation manifested as a non-classical CAH phenotype, and Tardy et al. [22]
measured the relative activity of an R234K mutation in vitro and showed that it is comparable to the
I231T mutant (which also manifests as non-classical CAH [19]). The deletion leads to the rotation of
R234 outwards, toward the solvent, rather than facing and interacting with the progesterone molecule.
Indeed, when computationally predicting the structure with E232 having been deleted, the Phyre2
web-server [20] demonstrates this precisely. Such a rotation in the positioning of the R234 is expected to
significantly impair the enzyme’s ability to hydrolase its substrate. We followed this in silico analysis
with in vitro studies.
2.4. In Vitro Biochemical Evaluation of Enzymatic Activity
To assess the impact of the novel E232del variant on the steroid 21-hydroxylase activity,
we expressed the wild type (WT) and E232del CYP21A2 in non-steroidogenic COS1 cells and quantified
the hydroxylase activity for both the WT and variant proteins. Using thin layer chromatography,
we found that this mutation negatively affects the hydroxylase activity of steroid 21-hydroxylase for
both progesterone and 17-OH progesterone substrates compared to the WT-CYP21A2 (4% and 1%,
respectively) (Figure 2A). To determine whether the reduced activity of E232del-CYP21A2 is associated
with decreased expression of the protein, we quantified both E232del-CYP21A2 and WT-CYP21A2
expression using Western blot analysis. We found that the E232del mutation reduces the expression of
steroid 21-hydroxylase to 22% compared to the WT form (Figure 2B). We calculated the specific activity
of E232del-CYP21A2 compared to the WT-CYP21A2, by dividing the activity obtained by TLC by the
protein level. The specific activity of E232del-CYP21A2 was decreased to 16% compared to the WT
protein. Altogether, our results indicated that the E232del mutation significantly impacted both the
expression and activity of steroid 21-hydroxylase.
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Figure 2. CYP21A2-E232del affects protein levels and 21-hydroxylase activity. Legend: (A) Left-hand
panel: thin layer chromatography (TLC) shows t at E232del variant markedly reduces the hy roxylase
activity of CYP21A2. Right-panel: substrate conversion is calculated after densitometric quantification
of the relative incorporation of radioactivity in specific TLC spots. Conversion of progesterone
(Prog) to 11-deoxycorticosterone (11DOC) in the mutated protein (E232del-CYP21A2) is reduced
to an average of 4% compared to the wild-type form of the protein (WT-CYP21A2). Conversion of
17-hydroxyprogesterone (17-OH Prog) to 11-deoxycortisol (DOC) is reduced to an average of 1%. (B) Left
panel: Western blot analysis of protein levels following overexpression of CYP21A2 in non-steroidogenic
COS1 cells shows reduced expression of the protein carrying the E232del variant compared to the
wild-type form. Right panel: densitometric quantification of the blot indicating that E232del mutation
reduces CYP21A2 expression to 22% on average. (C) Relative specific activity was calculated by
dividing the values of substrate conversion (Panel A) by the paired protein level values (Panel B).
The E232del variant then reduces CYP21A2-mediated activity to 16% on average. Statistical analysis
was conducted as described in the Methods section. The bars in Panel A were analyzed using a two-way
ANOVA analysis followed by post hoc Sidak’s multiple comparison test. The bars in Panel B were
analyzed using a two-tailed Student’s t-test. The bars in Panel C were analyzed using a two-tailed
Welch t-test. The error bars indicate the standard error of the mean (SEM). Every experiment was run
with three independent biological replicates, each time using technical triplicates. ****, p ≤ 0.0001.
3. Discussion
We present a detailed mechanistic investigation of the molecular phenotype of a novel de novo
in-frame deletion c.694_696del that was found in a compound heterozygote state with a larger deletion
comprising the whole CYP21A2 gene, in a patient diagnosed as having classical salt-wasting CAH.
The E232del variant results in the deletion of a non-conserved amino acid (glutamic acid at
position 232) and thus was initially interpreted to be a variant of uncertain significance. CAH is
a serious life-threatening condition. Molecular diagnosis can be crucial for families, since it may
affect counseling and future pregnancy planning. In recent years, a surge of clinically directed
genetic tests has become available, dramatically increasing diagnostic yield and improving medical
management and genetic counselling [23–30]. However, these new opportunities bear significant
challenges. One major challenge is interpreting and analyzing rare sequence variants that are not
necessarily clinically relevant [31,32]. In particular, the impact of changes, such as missense and
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in-frame indel variants might be more difficult to interpret. On average, 2% of the population carry
a missense variant in any given gene, emphasizing the extent of this difficulty [33]. Similar to the result
in our case, even when a new variant is highly suspicious of being pathogenic, without functional
reasoning, pathogenicity remains uncertain [27] and additional investigation methods are required.
In vitro biochemical assays are key to the study of novel gene variants and the results in the
presented case are in agreement with the clinical presentation of classical salt-wasting CAH.
However, such investigations are time- and resource-consuming, emphasizing the importance of
correctly choosing the relevant functional assay. Different assays might be used based on the
particular aspect of the protein’s function under assessment. For example, assays that characterize
variants interfering with an enzyme’s active site differ from those directed at evaluating its rate
of degradation [34,35]. Thus, to better understand specific variants in patients and to plan the
functional assays, one needs a mechanistic understanding of the impact of the variant. To this end,
in-silico approaches can be extremely helpful.
We used computational methods to determine the effect of the gene variant on the steroid
21 hydroxylase enzyme. Our analysis findings suggest that the variant affects the intra-helical
positioning of amino acids downstream from the deleted residue. This significantly impairs the proteins’
electrostatic stability and enzymatic function. Structural models can explain not only missense variants,
but also more complicated cases, such as deletions of a single amino acid, as demonstrated in our
patient. Accurate crystallography-based analysis of the protein structure is critical to a mechanistic
model [36–39]. Based on our analysis, we further predict that missense mutations among variants
in the CYP21A2 gene residues in the helix G preceding the R234, starting at residue 225 and facing the
solvent (R225 R226 Q229 A230 E232 K233), will not be very harmful, but that deletions and perhaps
insertions will disrupt the function of the protein.
In conclusion, c.694_696del is a novel variant of the CYP21A2 gene causing classical salt-wasting
CAH, broadening the spectrum of known mutations related with CAH. This case demonstrates the
mechanistic insights that can be gained from a comprehensive computational analysis based on
evolutionary information and structure prediction. We believe that the large numbers of possible
genetic variants and their potential effects dictate the implementation of computational tools to support
clinicians and scientists in the interpretation of genetic test results.
4. Materials and Methods
4.1. Genetic Analysis
Genetic testing was performed on clinical grounds with the approval of the Rambam Healthcare
Campus institutional ethics board. Tests were performed on peripheral blood-derived DNA samples
from the patient and both of her parents who gave their written informed consent for testing and
publication. Multiplex ligation-dependent probe (MLPA) analysis (SALSA MLPA Probemix P050-C1 kit,
MRC Holland, Amsterdam, The Netherlands) was performed to detect gene deletions and duplications.
Sanger sequencing was performed for the entire CYP21A2 gene by means of two-step PCR amplification
to specifically amplify the CYP21A2 gene, as previously described [40]. For gene sequencing, capillary
electrophoresis was implemented using the 3500 genetic analyzer. The results were analyzed with
Sequencher v5.0 (Gene Codes Corporation, Ann Arbor, MI, USA).
4.2. In Silico Studies: Mechanistic Analysis of Protein Function with a Three-Dimensional Molecular
CYP21A2 Model
The structure of the human CYP21A2 protein complexed with progesterone or with
17-hydroxyprogesterone was solved by Egli, Guengeric and co-workers, and it was deposited in the
Protein DataBank (ID 4Y8W) [7,8]. To understand the significance of the molecular phenotype of this
mutation, we relied on evolutionary data for comparing homologous proteins [36]. We used the ConSurf
suite [14–18] to deduce the effect of the mutation on the structure and function of protein residues
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based on their evolutionary conservation in homologous proteins. We mapped this information back
to the three-dimensional structure of the protein and manually assessed the effect on the proteins’
structure and enzymatic activity.
4.3. Biochemical Evaluation of Enzymatic Activity
4.3.1. Cell Transfection and Steroid Profiling
COS1 cells were transfected with 3 µg of mammalian expression plasmid (pcDNA3.1 (+),
Addgene) containing the full coding sequence of WT-CYP21A2 or E232del-CYP21A2 genes (GenScript).
Both coding sequences were flanked by a DYK (FLAG) tag expressed at the C terminal of the
protein. Experiments were performed in 12-well plates (3 × 105 cells/well). Transfection was
performed with Lipofectamine 2000 (Thermo Fisher, Waltham, MA, USA) for 4 h, after which the
growth media was replaced. At 48 h after transfection, new media were added containing both
80,000 cpm of [H3]-progesterone and [H3]-17-OH-progesterone, corresponding to a substrate about
15 nM. The medium was collected 90 min after. The amount of radioactive tracer steroids and time of
incubation were chosen based on previously published work that established the ability to convert
progesterone to 11-deoxycorticosterone and 17-OH-progesterone to 11-deoxycortisol in a cell-based
system [41]. Steroids were extracted and separated by thin layer chromatography (TLC) as previously
described. Relative steroid conversion was quantified as a percentage of incorporated radioactivity
into 11-deoxycorticosterone and 11-deoxyxortisol in relation to total radioactivity measured in the
whole sample and compared between the WT-CYP21A2 and the CYP21A2 variants.
4.3.2. Western Blot
For protein analysis, transfected cells were washed with ice-cold PBS and harvested in lysis
buffer containing 14.6 mg EDTA, 121 mg trisaminomethane (Tris), 435 mg NaCl, 0.5 mL Triton X-100
(Thermo Fisher) and cOmpleteTM protease inhibitor cocktail (Roche, Basel, Switzerland) in 50 mL of
water. Seven µg of total protein were then loaded on a precast gradient gel (GenScript, Piscataway,
NJ, USA, Cat# M81615). Proteins were transferred on a PVDF membrane at 4 ◦C overnight and
blocked with 5% non-fat milk in tris-buffered saline (TBS) supplemented with 0.1% Tween-20 (TBST).
The following primary antibodies were used: mouse anti-FLAG (GenScript, Cat# A00187), diluted
1:1000, and rabbit anti-GAPDH (Santa Cruz, CA, USA Cat# sc-25778), diluted 1:1500. Incubation with
primary antibodies was performed in 1% non-fat milk in TBST, overnight at 4 ◦C with mild rocking.
The following secondary antibodies were used: IRDye 680RD-conjugated donkey-anti-mouse (LI-COR,
Lincoln, NE, USA, Cat# 926-86072), diluted 1:10,000, and IRDye 800CW-conjugated donkey-anti-rabbit
(LI-COR, Cat# 926-32213), diluted 1:5000. Incubation with secondary antibodies was performed in 1%
non-fat milk in TBST at room temperature for 1 h with mild rocking. Membranes were washed with
TBST, and signals were detected by the Odyssey® Sa infrared Imaging system (LI-COR Bioscience Inc.).
4.3.3. Statistics
Statistical significance was calculated with a two-tailed Student’s t-test for comparing two groups.
For every two-group comparison, we ran an F-test to assess whether those two groups had different
variances. If there were a different variance, the two-tailed Welch t-test was used instead of the
Student’s t-test. Graphs with more than two groups were analyzed by two-way ANOVA analysis
followed by post hoc Sidak’s multiple comparison test. Prism 8 (Graphpad, San Diego, CA, USA) and
Excel (Microsoft, Redmond, WA, USA) were used for the statistical analyses and calculations.
Informed consent was obtained from the patient’s guardian for publication of the case report.
The study was presented to our institutional review board (IRB) and approval was waived based on
the clinical nature of the investigations performed.
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